2021
Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy
Wells CR, Cao Y, Durham DP, Byrareddy SN, Ansari AA, Ruddle NH, Townsend JP, Galvani AP, Perelson AS. Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. PLOS Computational Biology 2021, 17: e1009031. PMID: 34106916, PMCID: PMC8189501, DOI: 10.1371/journal.pcbi.1009031.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyViral loadPost-treatment controlAnti-α4β7 antibodyViral remissionAntibody treatmentViral controlCombinations of cARTImmune effector cell responsesPost-treatment viral controlSIV RNA copies/Depletion of CD8Ongoing immune responseEarly SIV infectionRNA copies/Stable viral loadEffector cell responsesViral load dataDifferent viral loadsAbsence of treatmentSubset of animalsNonhuman primate experimentsDifferent primary mechanismsLongitudinal viral load dataCART cessation
2016
Vaccination strategies against respiratory syncytial virus
Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP. Vaccination strategies against respiratory syncytial virus. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 13239-13244. PMID: 27799521, PMCID: PMC5135296, DOI: 10.1073/pnas.1522597113.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyncytial virusVaccination strategiesAge-specific vaccination strategiesRSV vaccine candidatesSubstantial indirect protectionInfectious viral loadOngoing clinical trialsWeekly incidence ratesTargeting of childrenDifferent age groupsInfected childrenRSV vaccinationVaccination uptakeInfant hospitalizationViral loadVaccine mechanismVaccination programClinical trialsIncidence rateCommon causeRSV incidenceVaccine candidatesAge groupsRSV symptoms